[go: up one dir, main page]

MX2019010422A - Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta. - Google Patents

Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.

Info

Publication number
MX2019010422A
MX2019010422A MX2019010422A MX2019010422A MX2019010422A MX 2019010422 A MX2019010422 A MX 2019010422A MX 2019010422 A MX2019010422 A MX 2019010422A MX 2019010422 A MX2019010422 A MX 2019010422A MX 2019010422 A MX2019010422 A MX 2019010422A
Authority
MX
Mexico
Prior art keywords
related disorders
pi3kî
treatment
pyrazolopyrimidine derivatives
formula
Prior art date
Application number
MX2019010422A
Other languages
English (en)
Inventor
Li Yun-Long
P Combs Andrew
W Yue Eddy
Mei Song
Zhu Wenyu
Glenn Joseph
B Sparks Richard
Douty Brent
He Chunhong
P Maduskuie Thomas Jr
Yao Wenqing
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of MX2019010422A publication Critical patent/MX2019010422A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente solicitud proporciona métodos para tratar trastornos relacionados con PI3Kd utilizando compuestos de la Fórmula I: (ver Fórmula) o sales farmacéuticamente aceptables de los mismos.
MX2019010422A 2013-03-01 2015-08-28 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta. MX2019010422A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361771480P 2013-03-01 2013-03-01

Publications (1)

Publication Number Publication Date
MX2019010422A true MX2019010422A (es) 2019-10-15

Family

ID=50288319

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015011273A MX367713B (es) 2013-03-01 2014-02-28 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.
MX2019010422A MX2019010422A (es) 2013-03-01 2015-08-28 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015011273A MX367713B (es) 2013-03-01 2014-02-28 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.

Country Status (32)

Country Link
US (6) US9932341B2 (es)
EP (3) EP2961410B1 (es)
JP (5) JP6545106B2 (es)
KR (5) KR20240152422A (es)
CN (2) CN105120871B (es)
AR (1) AR094964A1 (es)
AU (5) AU2014223257B2 (es)
BR (1) BR112015020941A2 (es)
CA (1) CA2901993C (es)
CL (1) CL2015002442A1 (es)
CR (1) CR20150472A (es)
CY (1) CY1122712T1 (es)
DK (1) DK2961410T3 (es)
EA (2) EA202192151A1 (es)
ES (2) ES2945212T3 (es)
HR (1) HRP20200263T1 (es)
HU (1) HUE047719T2 (es)
IL (6) IL311666A (es)
LT (1) LT2961410T (es)
MX (2) MX367713B (es)
MY (1) MY177875A (es)
PE (1) PE20151996A1 (es)
PH (3) PH12021552233A1 (es)
PL (1) PL2961410T3 (es)
PT (1) PT2961410T (es)
RS (1) RS59958B1 (es)
SG (3) SG10201707130UA (es)
SI (1) SI2961410T1 (es)
SM (1) SMT202000043T1 (es)
TW (5) TWI657090B (es)
UA (1) UA119641C2 (es)
WO (1) WO2014134426A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2766100C (en) 2009-06-29 2018-05-22 Incyte Corporation Pyrimidinones as pi3k inhibitors
KR102131612B1 (ko) 2011-09-02 2020-07-08 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ES2790419T3 (es) 2013-01-15 2020-10-27 Incyte Holdings Corp Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM
TWI657090B (zh) 2013-03-01 2019-04-21 英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
LT3129021T (lt) 2014-04-08 2020-12-10 Incyte Corporation B ląstelių piktybiškumo gydymas jak ir pi3k inhibitorių deriniu
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
SI3831833T1 (sl) * 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
ES2833955T3 (es) 2016-01-05 2021-06-16 Incyte Corp Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma
KR102375929B1 (ko) 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. 인돌린 유사체 및 이의 용도
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
JP7128264B2 (ja) * 2017-09-08 2022-08-30 ベイジーン リミテッド ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
RS63806B1 (sr) * 2018-01-10 2023-01-31 Idorsia Pharmaceuticals Ltd Derivati 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona i srodna jedinjenja kao modulatori c5a receptora za lečenje vaskulitisa i inflamatornih bolesti
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
IL278889B2 (en) * 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110833552A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
CR20250050A (es) * 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
WO2022115762A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
CN112808550B (zh) * 2020-12-28 2021-10-01 青岛理工大学 用于海洋工程的劣化免疫仿生防护界面及制备方法
WO2023114369A2 (en) 2021-12-16 2023-06-22 Incyte Corporation Topical formulations of pi3k-delta inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
HUP0401982A3 (en) 2001-09-19 2012-09-28 Aventis Pharma Sa Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds
HU230798B1 (hu) 2001-10-30 2018-06-28 Novartis Ag Staurosporin-származékok mint az FLT3 receptor tirozin-kináz aktivitás inhibitorai
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
EP1758892B1 (en) 2004-06-10 2012-10-17 Irm Llc Compounds and compositions as protein kinase inhibitors
MX2007006204A (es) 2004-11-24 2007-06-20 Novartis Ag Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
TWI423976B (zh) 2006-01-17 2014-01-21 Vertex Pharma 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
WO2009157880A1 (en) 2008-06-27 2009-12-30 S*Bio Pte Ltd Pyrazine substituted purines
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
CA2738429C (en) * 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
CN102395363A (zh) 2009-04-09 2012-03-28 肿瘤防护公司 Pi-3激酶抑制剂用于治疗纤维化的方法和其组合物
CA2766100C (en) 2009-06-29 2018-05-22 Incyte Corporation Pyrimidinones as pi3k inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
PL2470546T3 (pl) 2009-08-28 2013-12-31 Takeda Pharmaceuticals Co Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102131612B1 (ko) * 2011-09-02 2020-07-08 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TWI657090B (zh) * 2013-03-01 2019-04-21 英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
WO2015191677A1 (en) * 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
SI3831833T1 (sl) * 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
US11161838B2 (en) * 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors

Also Published As

Publication number Publication date
JP2019142941A (ja) 2019-08-29
SI2961410T1 (sl) 2020-03-31
IL240784A0 (en) 2015-10-29
KR20210110409A (ko) 2021-09-07
US20190040067A1 (en) 2019-02-07
EA202192151A1 (ru) 2021-12-31
CA2901993A1 (en) 2014-09-04
TWI736135B (zh) 2021-08-11
PH12019501321A1 (en) 2020-10-12
PL2961410T3 (pl) 2020-05-18
SG11201506654UA (en) 2015-09-29
KR102298150B1 (ko) 2021-09-07
KR20220143146A (ko) 2022-10-24
KR20230145517A (ko) 2023-10-17
AU2020210278B2 (en) 2022-05-26
US20140249132A1 (en) 2014-09-04
CR20150472A (es) 2016-01-04
PH12015501920A1 (en) 2016-01-18
UA119641C2 (uk) 2019-07-25
IL283943B1 (en) 2023-04-01
AU2024287194A1 (en) 2025-01-23
TWI687220B (zh) 2020-03-11
CN109010343A (zh) 2018-12-18
EP3632442B1 (en) 2023-04-05
TW201929860A (zh) 2019-08-01
JP2023036609A (ja) 2023-03-14
BR112015020941A2 (pt) 2017-07-18
TWI657090B (zh) 2019-04-21
TW202214254A (zh) 2022-04-16
KR20150135327A (ko) 2015-12-02
IL283943B2 (en) 2023-08-01
TW202333734A (zh) 2023-09-01
IL267853A (en) 2019-09-26
TW201444846A (zh) 2014-12-01
EP2961410A1 (en) 2016-01-06
JP2016510035A (ja) 2016-04-04
US20220119393A1 (en) 2022-04-21
LT2961410T (lt) 2020-02-10
PH12021552233A1 (en) 2022-07-18
HRP20200263T1 (hr) 2020-05-29
JP2021020914A (ja) 2021-02-18
AU2022218495B2 (en) 2024-10-03
JP7556010B2 (ja) 2024-09-25
IL274771A (en) 2020-07-30
CY1122712T1 (el) 2021-03-12
MX2015011273A (es) 2015-12-03
PH12015501920B1 (en) 2016-01-18
US20250289823A1 (en) 2025-09-18
SG10201707130UA (en) 2017-10-30
KR102717616B1 (ko) 2024-10-16
WO2014134426A1 (en) 2014-09-04
AR094964A1 (es) 2015-09-09
SG10201912275YA (en) 2020-04-29
CN105120871B (zh) 2018-08-10
US20210332059A1 (en) 2021-10-28
IL301180A (en) 2023-05-01
AU2018264053A1 (en) 2018-12-06
EP3632442A1 (en) 2020-04-08
KR20240152422A (ko) 2024-10-21
IL283943A (en) 2021-07-29
EP4233869A3 (en) 2023-11-01
MX367713B (es) 2019-09-03
JP7189185B2 (ja) 2022-12-13
CL2015002442A1 (es) 2016-02-05
TW202019428A (zh) 2020-06-01
HUE047719T2 (hu) 2020-05-28
IL267853B (en) 2020-03-31
IL311666A (en) 2024-05-01
JP2025003975A (ja) 2025-01-14
EP2961410B1 (en) 2019-12-11
PH12019501321B1 (en) 2020-10-12
US12152033B2 (en) 2024-11-26
AU2018264053B2 (en) 2020-08-20
ES2945212T3 (es) 2023-06-29
CN105120871A (zh) 2015-12-02
CA2901993C (en) 2023-03-07
EP4233869A2 (en) 2023-08-30
AU2022218495A1 (en) 2022-09-08
RS59958B1 (sr) 2020-03-31
SMT202000043T1 (it) 2020-03-13
JP6545106B2 (ja) 2019-07-17
HK1221398A1 (en) 2017-06-02
KR102454308B1 (ko) 2022-10-14
AU2020210278A1 (en) 2020-08-20
PE20151996A1 (es) 2016-01-13
US20220106318A1 (en) 2022-04-07
MY177875A (en) 2020-09-24
TWI841376B (zh) 2024-05-01
PT2961410T (pt) 2020-03-02
KR102586858B1 (ko) 2023-10-11
EA201591612A1 (ru) 2016-05-31
DK2961410T3 (da) 2020-02-17
AU2014223257A1 (en) 2015-09-24
JP6776399B2 (ja) 2020-10-28
IL240784B (en) 2020-06-30
US9932341B2 (en) 2018-04-03
AU2014223257B2 (en) 2018-11-29
ES2774436T3 (es) 2020-07-21

Similar Documents

Publication Publication Date Title
MX2019010422A (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.
CR20150571A (es) Compuestos y composiciones terapéuticos
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
JOP20140104B1 (ar) مركبات ثنائى اريل اميد كمثبطات كيناز
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
MX382991B (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
DOP2015000274A (es) Compuestos químicos
UY36716A (es) Moduladores de receptores nucleares
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
MX2015009479A (es) Compuestos y metodos para tratar infecciones bacterianas.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2016004841A (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam